INR731 for Prostate Cancer

This trial tests a new treatment, INR731, for individuals with metastatic prostate cancer, meaning the cancer has spread to other parts of the body. The study aims to determine the safety and tolerability of INR731, both alone and in combination with existing prostate cancer treatments, to assess its potential in fighting tumors. Participants should have prostate cancer that has metastasized and must be undergoing hormone therapy with evidence of the disease on imaging scans. As a Phase 1 trial, this research focuses on understanding how INR731 works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot use medications that prolong the QT interval unless you can stop them for the study. Also, you must not have taken an investigational agent within 7 days before starting the trial.

Research shows that INR731 is under study for safety and tolerability in treating prostate cancer, either alone or with other medications like enzalutamide or abiraterone.

For INR731 alone, early studies are still assessing its safety. This marks the first time INR731 is tested in humans, so detailed safety information is still being collected.

When combined with enzalutamide, it is important to note that enzalutamide's safety is well-established. It has been shown to lower the risk of death by 33% in patients with metastatic prostate cancer and is generally well-tolerated, with manageable side effects.

For the combination with abiraterone, past research has demonstrated that abiraterone is relatively safe and has fewer serious side effects compared to standard treatments. It also reduces the risk of death by nearly 40% for men with high-risk advanced prostate cancer.

Unlike the standard treatments for prostate cancer, which often include hormone therapies like enzalutamide and abiraterone alone, INR731 is being tested both as a single agent and in combination with these drugs. Researchers are excited about INR731 because it may offer a new mechanism of action that targets prostate cancer cells differently than existing therapies. This could potentially enhance the effectiveness of current hormone treatments and offer a more robust approach to managing the disease. By exploring these combinations, INR731 aims to improve patient outcomes and broaden the arsenal of tools available to fight prostate cancer.

Research has shown that INR731, which participants in this trial may receive, may help treat prostate cancer. Early studies suggest it could shrink tumors. In this trial, some participants will receive INR731 with enzalutamide, a drug that can lower the risk of death by 33% in prostate cancer patients, potentially improving treatment outcomes. Enzalutamide alone has been shown to extend life and enhance quality of life. Other participants will receive INR731 with abiraterone, which has increased survival by 40% in high-risk cases, potentially offering significant benefits. Overall, these combinations aim to enhance treatment effectiveness for advanced prostate cancer.¹³⁶⁷⁸